Recombinant Mouse Baculoviral IAP repeat-containing protein 7 (Birc7)
Description
Functional Mechanisms
Recombinant Mouse Birc7 exerts its anti-apoptotic effects via:
-
Caspase Inhibition: Direct binding and inhibition of caspases-3, -7, and -9, preventing proteolytic activation of apoptotic pathways .
-
Ubiquitination: Degradation of pro-apoptotic factors like DIABLO/SMAC through E3 ubiquitin ligase activity, thereby promoting cell survival .
-
Pathway Modulation: Interaction with NF-κB and MAPK signaling pathways to regulate cell proliferation and stress responses .
Research Applications
This recombinant protein is widely used in:
Key Research Findings
-
Cancer Biomarker: Elevated Birc7 mRNA levels correlate with poor prognosis in prostate cancer (497 tumor vs. 52 normal tissues) .
-
Therapeutic Target: Inhibitors targeting Birc7’s BIR domain show potential in sensitizing tumors to chemotherapy .
-
Dual Roles: While primarily anti-apoptotic, Birc7 may paradoxically enhance apoptosis under specific cellular stressors, highlighting context-dependent functions .
Production and Quality Control
The recombinant protein is produced with >90% purity, validated via SDS-PAGE and Western blot . Stability is ensured through storage at -80°C, avoiding repeated freeze-thaw cycles .
Clinical Relevance
Studies using recombinant Birc7 have revealed its overexpression in cancers like adrenocortical carcinoma (ACC), where it correlates with tumor aggressiveness but not necessarily patient survival . Ongoing research explores its utility as a prognostic marker and therapeutic target .
